The Cohen Rosenthal Diabetic Hypertensive Rat (CRDH) model

Summary of the technology

CRDH, rat, hypertension, diabetes, insulin resistance, end organ damage, heart, kidney, brain, AII antagonists, ACE inhibitors, CCB, TZDs, fixed combinations, allylmercaptopril, endothelin, adiponectin.


Project ID : 12-2013-434

Details of the Technology Offer

The construction of the Cohen Rosenthal Diabetic Hypertensive Rat (CRDH) model was initiated nearly a decade ago by cross-breeding between the Cohen Diabetic rat (CDR) and the SHR. The CDR is a rodent model that expresses the following phenotypes: when fed regular diet, it is non-diabetic; when fed a diabetogenic diet, it invariably develops diabetes reminiscent of type 2 in humans. The high-sucrose copper-poor diet consists of 18% casein, 72% sucrose, 4.5% butter, 0.5% corn oil, 5% salt No. II USP, water, and fat-soluble vitamins. Thus, a diet very poor in copper is required to develop the full diabetic phenotype. An outstanding feature of the CRDH rat is that it is a nonobese model of diabetes, which allows dissociation of the confounding obesity factor from other diabetogenic genes. Its pathology includes severe diffuse diabetic glomerulosclerosis and severe hypertensive changes in arteries and arterioles, characterized by fibrinoid necrosis and/or "onion skin" lesions, as well as by smooth muscle cell hyperplasia. Such vascular changes were not observed in the CDR or in the SHR. Diffuse glomerulosclerosis with marked expansion of mesangial matrix as well as lipohyalin lesions were also occasionally observed. Myocardial changes are prominent, with foci of ischemic necrosis and hyperplasic vascular changes. CRDH rats undergo cardiac hypertrophy and vascular changes affecting small-sized coronary arteries.

This animal model was used as an experimental tool for the investigation of therapeutic agents including telmisartan and other agents such as enalapril, losartan lercanidipine, endothelin antagonist-LU-135252, and allyl-mercaptocaptopril in collaboration with Weizmann institute of science.

We can provide a full spectrum of analysis for in vitro and in vivo assays, enabling us to evaluate and characterize the effects of drugs on kidney,heart and brain.

Contact:

Prof. Rosenthal Talma, MD
Department of Physiology and Pharmacology
Sackler School of Medicine
Tel/Fax- 03-640-6637

E-mail-rtalma@post.tau.ac.il

Project manager

avi Wener
Research services

Project researchers

Talma Rosenthal
T.A.U Tel Aviv University, Medicine-Sackler Faculty
Physiology and Pharmacology

Related Keywords

  • Biology / Biotechnology
  • Services
  • Life Sciences and Biotechnology
  • Life Sciences and Biotechnology
  • Drug delivery
  • Life Sciences and Biotechnology
  • Research / Development tools
  • Pharmaceutical Indications
  • Cardiovascular
  • Life Sciences and Biotechnology
  • animal models
  • Pharmaceutical Indications
  • animal models

About RAMOT at Tel Aviv University Ltd.

Ramot is Tel Aviv University's (TAU) technology transfer company and its liaison to industry, bringing promising scientific discoveries made at the university to industry's attention. The company provides the legal and commercial frameworks for inventions made by TAU faculty, students and researchers, protecting discoveries with patents and working jointly with industry to bring scientific innovations to the market.

RAMOT at Tel Aviv University Ltd.

Never miss an update from RAMOT at Tel Aviv University Ltd.

Create your free account to connect with RAMOT at Tel Aviv University Ltd. and thousands of other innovative organizations and professionals worldwide

RAMOT at Tel Aviv University Ltd.

Send a request for information
to RAMOT at Tel Aviv University Ltd.

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support